Trending Up0.0185 (3.2090%)
  • Bid / Lots
    0.5500/ 10
  • Ask / Lots
    0.6354/ 1
  • Open / Previous Close
    0.5700 / 0.5765
  • Day Range
    Low 0.5700
    High 0.5979
  • 52 Week Range
    Low 0.5421
    High 2.7800
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.5765
09:32 ET3240.57
09:39 ET100000.571
09:43 ET36500.58
09:48 ET5000.5711
09:52 ET10000.5725
09:57 ET4500.5799
09:59 ET15500.5798
10:01 ET101910.5797
10:03 ET21000.5797
10:39 ET2770.5782
10:44 ET211510.5712
10:46 ET50000.5865
10:50 ET5000.5979
10:51 ET15000.5865
10:57 ET11760.5865
11:02 ET1660.5965
11:04 ET62050.5732
11:08 ET40000.577757
11:13 ET10000.592099
11:15 ET20000.592
12:21 ET1000.5801
12:34 ET4000.5816
12:38 ET100000.5869
12:39 ET9000.5857
12:56 ET3890.5856
01:06 ET40000.5857
01:10 ET1000.5856
01:17 ET1000.5856
01:21 ET73000.58561
01:32 ET61840.585
02:02 ET1000.5829
02:20 ET1000.5802
02:24 ET73620.5803
02:26 ET3500.5876
02:36 ET27000.585
02:54 ET1500.5935
03:05 ET25000.5819
03:14 ET8000.5877
03:57 ET1000.595
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAPTO
Aptose Biosciences Inc
United StatesNMTR
9 Meters Biopharma Inc
United StatesONCY
Oncolytics Biotech Inc
United StatesGMTX
Gemini Therapeutics Inc
United StatesSNSE
Sensei Biotherapeutics Inc
United StatesIMNM
Immunome Inc
As of 2022-10-01

Company Information

Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.

Contact Information

251 Consumers Rd Suite 1105NORTH YORK, ON, Canada M2J 4R3


Chairman of the Board, President, Chief Executive Officer, Chief Accounting Officer
William Rice
Chief Financial Officer, Senior Vice President
Fletcher Payne
Senior Vice President, Chief Medical Officer
Rafael Bejar
Chief Commercial Officer
Philippe Ledru
Lead Independent Director
Denis Burger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.